During the last session, Sage Therapeutics Inc (NASDAQ:SAGE)’s traded shares were 0.87 million, with the beta value of the company hitting 0.87. At the end of the trading day, the stock’s price was $5.17, reflecting an intraday gain of 6.60% or $0.32. The 52-week high for the SAGE share is $28.26, that puts it down -446.62 from that peak though still a striking 10.64% gain since the share price plummeted to a 52-week low of $4.62. The company’s market capitalization is $316.27M, and the average intraday trading volume over the past 10 days was 0.9 million shares, and the average trade volume was 713.00K shares over the past three months.
Sage Therapeutics Inc (SAGE) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 2.85. SAGE has a Sell rating from 1 analyst(s) out of 8 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.47.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sage Therapeutics Inc (NASDAQ:SAGE) trade information
Sage Therapeutics Inc (SAGE) registered a 6.60% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.60% in intraday trading to $5.17, hitting a weekly high. The stock’s 5-day price performance is 1.37%, and it has moved by -34.14% in 30 days. Based on these gigs, the overall price performance for the year is -73.39%. The short interest in Sage Therapeutics Inc (NASDAQ:SAGE) is 6.0 million shares and it means that shorts have 8.29 day(s) to cover.
The consensus price target of analysts on Wall Street is $28, which implies an increase of 81.54% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $105 respectively. As a result, SAGE is trading at a discount of -1930.95% off the target high and 22.63% off the low.
Sage Therapeutics Inc (SAGE) estimates and forecasts
Statistics show that Sage Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Sage Therapeutics Inc (SAGE) shares have gone down -56.11% during the last six months, with a year-to-date growth rate more than the industry average at 28.18% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -168.71% this quarter and then jump 30.46% in the quarter after that. In the rating firms’ projections, revenue will decrease -51.09% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 14.16M as predicted by 17 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 16.52M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 77.97M and 7.9M respectively. In this case, analysts expect current quarter sales to shrink by -81.84% and then jump by 109.09% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -2.28%. While earnings are projected to return 28.02% in 2024, the next five years will return 16.80% per annum.
SAGE Dividends
Sage Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sage Therapeutics Inc (NASDAQ:SAGE)’s Major holders
Sage Therapeutics Inc insiders own 11.92% of total outstanding shares while institutional holders control 86.44%, with the float percentage being 98.13%. VANGUARD GROUP INC is the largest shareholder of the company, while 253.0 institutions own stock in it. As of 2024-06-30, the company held over 6.42 million shares (or 10.6696% of all shares), a total value of $69.68 million in shares.
The next largest institutional holding, with 5.82 million shares, is of FMR LLC’s that is approximately 9.6836% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $63.24 million.
Also, the Mutual Funds coming in first place with the largest holdings of Sage Therapeutics Inc (SAGE) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Fidelity Growth Company Fund . Data provided on Sep 30, 2024 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 1.68 shares. This amounts to just over 2.74 percent of the company’s overall shares, with a $8.68 million market value. The same data shows that the other fund manager holds slightly less at 1.6, or about 2.62% of the stock, which is worth about $8.28 million.
